Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (171-180 of 250) with videos related to

Pageof 25
Sort By:
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myelomaCamila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
Blood|September 18, 2024
Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myelomaNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Blood|December 1, 2011
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaBruno Paiva, Norma C Gutiérrez, Laura Rosiñol, et al.
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsJuan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2016
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple MyelomaCristina Jiménez, María Jara-Acevedo, Luis A Corchete, et al.
Haematologica|March 7, 2008
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progressionMaría-Victoria Mateos, José M Hernández, Miguel T Hernández, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Blood Cancer Journal|February 8, 2020
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patientsAlejandro Medina, Cristina Jiménez, M Eugenia Sarasquete, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Pageof 25

Showing results (171-180 of 250) with videos related to

Sort By:
Pageof 25
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myelomaCamila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
Blood|September 18, 2024
Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myelomaNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Blood|December 1, 2011
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaBruno Paiva, Norma C Gutiérrez, Laura Rosiñol, et al.
Hemasphere|December 12, 2024
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experienceVeronica González-Calle, Paula Rodriguez-Otero, Maria J Calasanz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2017
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsJuan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2016
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple MyelomaCristina Jiménez, María Jara-Acevedo, Luis A Corchete, et al.
Haematologica|March 7, 2008
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progressionMaría-Victoria Mateos, José M Hernández, Miguel T Hernández, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Blood Cancer Journal|February 8, 2020
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patientsAlejandro Medina, Cristina Jiménez, M Eugenia Sarasquete, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Pageof 25